Rate My Professor Andre Mu

Andre Mu is a Senior Lecturer and Laboratory Head in the Department of Biochemistry and Molecular Biology at Monash University, affiliated with the Biomedicine Discovery Institute's Infection Program and Metabolism, Diabetes, and Obesity Program. He earned his PhD in Microbiology from the University of Melbourne in 2016 and a Bachelor of Science with Honours in Microbiology from the same university in 2010. Over 14 years, Mu has trained at leading institutions across Australia, the United States, and the United Kingdom, supported by prestigious individual research fellowships totaling more than $411,000. These include the NOMIS Foundation Research Fellowship at the Salk Institute for Biological Studies, the EMBL-EBI and Sanger Research Fellowship at the Wellcome Sanger Institute and European Bioinformatics Institute, the Endeavour Research Fellowship at the Doherty Institute and University of California San Diego, and the NSERC International Exchange Fellowship at the University of Calgary. He also holds an Honorary Research Fellow position in the Department of Microbiology and Immunology at the University of Melbourne and served as a Visiting Research Fellow at UC San Diego with Professor Rob Knight.

As a microbial ecologist and bioinformatician, Andre Mu investigates the mechanisms by which commensal microorganisms influence host health and disease, focusing on the human gut microbiome and infectious diseases. His research employs culture-dependent and independent techniques, including multi-omics (metagenomics, transcriptomics, metabolomics), computational biology, and bacterial physiology assays to develop gut microbiome engineering strategies for therapeutic applications. Notable contributions include leading experimental phases of Bioplatforms Australia's Antibiotic Resistant Pathogens Initiative, identifying core targets in sepsis-causing bacteria, and characterizing microbiome responses to bacteriophage therapy in clinical infections. Key publications feature 'A gut microbial signature for combination immune checkpoint blockade across cancer types' in Nature Medicine (2024), 'Primary succession of Bifidobacteria drives pathogen resistance in neonatal microbiota assembly' in Nature Microbiology (2024), 'The growing repertoire of phage anti-defence systems' in Trends in Microbiology (2024), and 'Highly stable bacteriophages PIN1 and PIN2 have hallmarks of flagellotropic phages but infect immotile bacteria' in npj Viruses (2025). His work, cited over 1,457 times on Google Scholar, advances understanding of antibiotic resistance, phage therapy, and microbial succession.